Shares of Claris Lifesciences rose by over 3 per cent today as the US health regulator has found its manufacturing facility acceptable after an inspection.
The company's stock ended at Rs 168.60, up 3.31 per cent on the BSE. During the day, it gained 7.26 per cent to Rs 175.05.
On the volume front, 2.76 lakh shares of the company changed hands at the BSE in intra-day trade.
"Claris Lifesciences has announced that it has received a report from USFDA for the inspection it conducted classifying the finished dosage plant and the API plant as acceptable," the pharma company had said in a BSE filing yesterday.
The company has three manufacturing plants at its campus on the outskirts of Ahmedabad.
The company manufactures and markets products across various therapeutic segments including anesthesia, blood products, anti-infective and renal care.
